Rational Pharmacotherapy in Cardiology

Advanced search

Current Trends in the Treatment of Hypertension: Focus on Improving Prognosis. The Capabilities of an Amlodipine/Telmisartan Single-Pill Combination

Full Text:


Nowadays, the modern approach to antihypertensive therapy is to prescribe in the most hypertensive patients fixed-dose combinations of antihypertensive drugs as initial therapy. This concept is reflected in the latest revisions of European and Russian guidelines for the management of arterial hypertension (AH). Above mentioned principle is referred as “single-pill combination” strategy and is given high priority in clinical practice with a high evidence level. According to this approach, one of the possible first line single-pill combinations is the combination of an angiotensin II receptor blocker and a calcium channel blocker. In both classes, the reference and the best representatives include, respectively, telmisartan and amlodipine, as a result of broad experience in their practical application and, most importantly, extensive body of evidence regarding to its effectiveness and safety. Both antihypertensive drugs are distinguished by an extra-longstanding antihypertensive effect that exceeds such one of other representatives in their classes, thereby a stable blood pressure control throughout the day is realized, and most importantly, in the early morning hours, that are the most dangerous in terms of adverse cardiovascular and cerebrovascular events. Another important telmisartan and amlodipine characteristics is their targetorgan protective properties, which is realized at all the levels. In addition, telmisartan has a unique ability to activate PPAR-у-receptors and improves the carbohydrate metabolism and lipid profile, which is advantageous in patients with concomitant metabolic syndrome and diabetes mellitus. The telmisartan and amlodipine features and their proven ability to improve prognosis in hypertensive patients served as background for creating a singlepill combination of these antihypertensive drugs, which fully meet with the requirements of current clinical guidelines for AH management and in which these drugs synergistically coupling resulting in more effective blood pressure control, increases the reliability of target-organ protection, and also improves the therapy safety profile.

About the Authors

O. D. Ostroumova
Pirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Olga D. Ostroumova – MD, PhD, Head of Laboratory of Clinical Pharmacology and Pharmacotherapy, Russian Gerontology Clinical Research Center, Pirogov Russian National Research Medical University; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Sechenov University

Pervaya Leonova ul. 16, Moscow, 129226, 

Trubetskaya ul. 8-2, Moscow, 119991

A. I. Kochetkov
Pirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology
Russian Federation

Alexey I. Kochetkov – MD, PhD, Researcher, Laboratory of Clinical Pharmacology and Pharmacotherapy, Russian Gerontology Clinical Research Center, Pirogov Russian National Research Medical University; Assistant, Chair of Aging Diseases, Pirogov Russian National Research Medical University  

Pervaya Leonova ul. 16, Moscow, 129226


1. Williams B., Mancia G., Spiering W., et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.

2. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные Гипертензии. 2019;16(1):6-31. DOI:10.26442/2075082X.2019.1.190179.

3. Law M.R., Wald N.J., Morris J.K., Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427-31. DOI:10.1136/bmj.326.7404.1427.

4. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res. 2009;37(6):1662-79. DOI:10.1177/147323000903700602.

5. Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41-6.

6. Abraham H.M., White C.M., White W.B. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33-54. DOI:10.1007/s40264-014-0239-7.

7. Stangier J., Su C.A., van Heiningen P.N., et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38(5):672-85. DOI:10.1097/00005344-200111000-00004.

8. Ostroumova O.D., Maksimov M.L., Bondarets O.V. Angiotensin-converting enzyme inhibitors in the physician’s practice: similarities and differences. Meditsinskiy Sovet. 2011;5-6:50-7. (In Russ.)

9. Peixoto A.J., White W.B. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int. 2007;71(9):855-60. DOI:10.1038/

10. Willich S.N., Levy D., Rocco M.B., et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol. 1987;60:801-6. DOI:10.1016/00029149(87)91027-7.

11. Elliott W.J. Circadian variation in the timing of stroke onset. А meta-analysis. Stroke. 1998;29:9926. DOI:10.1161/01.STR.29.5.992.

12. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56(5):765-73. DOI:10.1161/HYPERTENSIONAHA.110.157149.

13. White W.B., Giles T., Bakris G.L., et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006;151(1):176-84. DOI:10.1016/j.ahj.2005.02.014.

14. Nishimura T., Hashimoto J., Ohkubo T., et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens. 2005;27(6):477-89. DOI:10.1081/CEH-200067668.

15. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J. 2004;148(1):52-61. DOI:10.1016/j.ahj.2004.03.020.

16. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/NEJMoa0801317.

17. Yusuf S., Teo K., Anderson C., et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-83. DOI:10.1016/S0140-6736(08)61242-8.

18. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5): 993-1002. DOI:10.1161/01.HYP.0000123072.34629.57.

19. Jugdutt B.I. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging. 2010;5:403-16. DOI:10.2147/CIA.S6709.

20. Wakino S., Ronald E.L., Hsueh W.A. Vascular protective effects by activation of nuclear receptor PPARγ. Journal of diabetes and its complications 2002;16(1):46-9. DOI:10.1016/S10568727(01)00197-0.

21. Hsueh W.A., Law R. The central role of fat and effect of peroxisome proliferator-activated receptorgamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003;92(4A):3J-9J. DOI:10.1016/s0002-9149(03)00610-6.

22. Schiffrin E.L., Amiri F., Benkirane K., et al. Peroxisome proliferator-activated receptors. Hypertension. 2003;42(4):664-8. doi:10.1161/01.HYP.0000084370.74777.B6.

23. Vitale C., Mercuro G., Castiglioni C., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology. 2005;4:6. DOI:10.1186/14752840-4-6.

24. Miura Y., Yamamoto N., Tsunekawa S., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005;28(3):757-8. DOI:10.2337/diacare.28.3.757.

25. Derosa G., Cicero A.F., D'Angelo A., et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res. 2006;29(11):849-56. DOI:10.1291/hypres.29.849.

26. Derosa G., Cicero A.F., Bertone G., et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubleblind study. Clin Ther. 2004;26(8):1228-36. DOI:10.1016/S0149-2918(04)80049-3.

27. Radchenko A.D. Some aspects of dihydropyridine calcium antagonists in the treatment of hypertension. Part 1. Arterialnaya Gipertenziia. 2013;5(31):81-98. (In Russ.)

28. Nissen S.E., Tuzcu E.M., Libby P., et al. for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-25. DOI:10.1001/jama.292.18.2217.

29. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-10. DOI:10.1161/01.cir.102.13.1503.

30. Jamerson K., Weber M.A., Bakris G.L., et al. for the Accomplish trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28. DOI:10.1056/NEJMoa0806182.

31. Dahlof B., Sever P.S., Poulter N.R., et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. DOI:10.1016/S01406736(05)67185-1.

32. Williams B., Lacy P.S., Thom S.M., et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. DOI:10.1161/CIRCULATIONAHA.105.595496.

33. Boitsov S.A. ASCOT Study an argument in the struggle between the New and the Old and a step towards the values revaluation. Consilium Medicum. 2006;11:5-11. (In Russ.)

34. Neldam S., Edwards C., Jones R.; TEAMSTA-10 Investigators. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin. 2011;27(11):2145-53. DOI:10.1185/03007995.2011.624089.

35. Sharma A., Bagchi A., Kinagi S.B., et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007;29(12):2667-76. DOI:10.1016/j.clinthera.2007.12.017.

36. Goyal J., Khan Z.Y., Upadhyaya P., et al. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014;8(6):HC08-11. DOI:10.7860/JCDR/2014/9352.4500.

37. Littlejohn T.W. 3rd, Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients.J Clin Hypertens (Greenwich). 2009;11(4):207-13. DOI:10.1111/j.17517176.2009.00098.x.

38. Neutel J.M., Mancia G., Black H.R., et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14(4):206-15. DOI:10.1111/j.1751-7176.2012.00595.x.

39. Fogari R., Zoppi A., Maffioli P., et al. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother. 2011;12(16):2441-8. DOI:10.1517/14656566.2011.623698.


For citations:

Ostroumova O.D., Kochetkov A.I. Current Trends in the Treatment of Hypertension: Focus on Improving Prognosis. The Capabilities of an Amlodipine/Telmisartan Single-Pill Combination. Rational Pharmacotherapy in Cardiology. 2019;15(6):906-917. (In Russ.)

Views: 1182

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)